Journal article icon

Journal article

Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.

Abstract:

The phase III Continuous or Intermittent (COIN) trial failed to show a benefit in overall survival (OS) of cetuximab in combination with chemotherapy for patients with metastatic colorectal cancer. High derived neutrophil to lymphocyte ratio (dNLR) has been shown to be prognostic in patients with metastatic colorectal cancer. The aim of this analysis is to evaluate dNLR as a predictive biomarker of the survival according to RAS and BRAF mutations status within the COIN trial. A post-hoc explo...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Role:
Author
ORCID:
0000-0003-3915-7243
Expand authors...
More from this funder
Grant:
MC_UU_12023/3
MC_U122861325
MC_UU_12023/20
G0701770
Publisher:
Lippincott, Williams and Wilkins Publisher's website
Journal:
Anti-Cancer Drugs Journal website
Volume:
28
Issue:
5
Pages:
546–550
Publication date:
2017-06-01
Acceptance date:
2017-02-06
DOI:
EISSN:
1473-5741
ISSN:
0959-4973
Pubs id:
pubs:685644
URN:
uri:01dd4a01-ca7a-49f2-b612-2f3bc90aef85
UUID:
uuid:01dd4a01-ca7a-49f2-b612-2f3bc90aef85
Local pid:
pubs:685644

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP